Simple Initiation of Advanced Hybrid Closed Loop System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-21

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background and Aim. The new and advanced hybrid closed loop (AHCL) system MiniMed 780G automatically adjusts basal insulin delivery in addition to automated bolus corrections, based on continuous glucose monitoring (CGM) readings, to offer protection against both hyperglycemia and hypoglycemia.

The objective of this study is to evaluate whether a simplified approach for patients' follow up using preset of pump settings and a simplified meal announcement, followed by minimal interaction can achieve similar glycemic control of AHCL system MiniMed 780G with Guardian Sensor 4 than a regular protocol that is currently used in adolescents with Type 1 Diabetes (T1D).

Methods. This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months. A total of 34 individuals (age 12-18 years) will be enrolled to reach 30 individuals who will complete the 3 months study. Participants will be randomized in two groups: Group 1, Regular Clinical Protocol, 17 participants and Group 2, Simplified Clinical Protocol, 17 participants.

All patients will be recruited during the regular clinic visits to the outpatient Endocrine Clinics at Sidra Medicine in Doha. Patients will be chosen on a first-come first-served basis. Inclusion criteria: Clinical diagnosis of type 1 diabetes, , Age 12-18 years, Basal Bolus therapy \>8.0 units per day. Exclusion criteria: Diabetic Ketoacidosis (DKA) in the 6 months prior to screening visit. The initiation protocol consists of four stages: HCL system compatibility assessment, HCL system training, Manual Mode Start and Auto Mode start. Patients will have 7 visits in a period of 3 months after initiation of insulin pump therapy.

Pump initiation: Group 1, Finetune ICR, Target 100 or 110 mg/dl and AIT: 2-3 hour and Group 2, Carb Ratio by formula 360 / TDD, ICR 8-10 (TDD 40-60), ICR 5-7 (TDD \>60), Target 100 mg/dl, AIT: 2 hours with fixed meals Results. No group difference in Time in Range (TIR) (70-180mg/dl) \> 70% and HbA1c \< 7.5% in a period of 3 months after initiation of AHCL.

Conclusion. Conclusions will be drawn on completion of the study and evaluation of the results.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An 8-Day Initiation of Advanced Hybrid Closed Loop System In Children and Adolescents

NCT04509362

Type 1 Diabetes

COMPLETED

Simple Meal Management Using Automated Insulin Delivery System

NCT06130215

Type 1 Diabetes

RECRUITING NA

Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections

NCT04145804

Type 1 Diabetes

UNKNOWN NA

Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)

NCT06919029

Diabetes Mellitus, Type I

RECRUITING

Evaluation of Minimed 670G in T1D Patients on Multiple Daily Injection

NCT03755479

Diabetes Mellitus, Type 1

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months.

A total of 34 individuals (age 12-18 years) will be enrolled to reach 30 individuals who will complete the 3 months study.

Participants will be randomized in two groups:

* Group 1, Regular Clinical Protocol, 17 participants
* Group 2, Simplified Clinical Protocol, 17 participants Intervention Description
* Intervention in Group 2, Simplified protocol.
* Insulin Carb Ratio (ICR) by formula 360 / Total Daily Dose (TDD)

* ICR 8-10 (TDD 40-60)
* ICR 5-7 (TDD \>60)
* Target 100 mg/dl
* Active Insulin Time (AIT): 2 hours
* Meals: Thee sets of meal set of meals announcement carbs calculated by the following formula:

* Regular meal: Total Carbs per Day x 0.6 / 3
* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5
* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5 \* Efficacy The efficacy shall be measured Time in Ranges (provided by CGM data), for Time in Range (70-180mg/dl), Time below Range(\<70mg/dl) and Time above Range (\>180 mg/dl) in the third month of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes type1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months.

Participants will be randomized in two groups:

* Group 1, Regular Clinical Protocol, 17 participants
* Group 2, Simplified Clinical Protocol, 17 participants

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Eligible subjects shall be randomly assigned to Group 1 or Group 2 in a 1:1 ratio using a computer-generated randomization scheme developed by the data manager.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1, Regular Protocol

Participants will bolus (insulin), based on carbohydrate content in each meal

Group Type ACTIVE_COMPARATOR

Regular Protocol with advanced carbohydrate counting

Intervention Type PROCEDURE

* Review 3 Days CGM data in Manual Mode
* Carb Ratio by formula 360 / TDD
* Finetune ICR
* Target 100 or 110 mg/dl
* AIT: 2-3 hour
* Insulin Bolus for meal (advanced carb counting)
* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.
* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use).

Group 2, Simplified protocol

Participants will bolus (insulin), based on three sets of meal set of meals announcement

Group Type EXPERIMENTAL

Simplified Protocol with fixed carbohydrate content

Intervention Type PROCEDURE

* Review 3 Days CGM data in Manual Mode
* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)
* Target 100 mg/dl
* AIT: 2 hours
* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5
* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.
* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regular Protocol with advanced carbohydrate counting

* Review 3 Days CGM data in Manual Mode
* Carb Ratio by formula 360 / TDD
* Finetune ICR
* Target 100 or 110 mg/dl
* AIT: 2-3 hour
* Insulin Bolus for meal (advanced carb counting)
* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.
* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use).

Intervention Type PROCEDURE

Simplified Protocol with fixed carbohydrate content

* Review 3 Days CGM data in Manual Mode
* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)
* Target 100 mg/dl
* AIT: 2 hours
* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5
* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.
* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinical diagnosis of type 1 diabetes \>0.5 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
2. Age 12-18 years and above at the initiation of the system
3. Total daily insulin use of great than 8.0 units per day over a 1-week period
4. Willing and able (access to internet from home)
5. Clinically able to start the AHCL system

Exclusion Criteria

1. Pregnancy
2. Untreated diabetes retinopathy, or other causes that in the investigator's opinion , precludes the individual from participating in the trial.
3. Currently in other Clinical Trial

Minimum Eligible Age

12 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No